Table 1

Survival rates in TAK according to specific disease features

NStudied groups
(follow-up duration)
Survival ratesP valueRoB
QUIPS tool
Ishikawa and Maetani18 120According to prognostic score classification.
Stage 1 vs 2 vs 3.
(median 13 years and 2 months)
100% vs 83.6% vs 43%<0.001Moderate
 Ishikawa15 81I+IIa vs IIb+III†.
At 5 years and 10 years.
(mean 7.4±5.8 years)
100% vs 74.2%<0.005Moderate
Soto et al 22 94Patients with coronary disease developing between 10 and 19 years vs between 20 and 39 years at 2, 5 and 10 years.50% at each time point vs 88% at each time pointHigh
Patients with hypertension developing between 10 and 19 years vs between 20 and 39 years at 2, 5 and 10 years.
(mean 75±83 months)
65% vs 87%
57% vs 87%
48% vs 87%
  • *Stages defined according to the presence or absence of three predictors, major complications, progressive disease course or low ESR (<20 mm/hour): stage 1 (0 predictor or only progressive disease or only low ESR), stage 2 (only major complication or progressive disease course and low ESR or major complication and low ESR) and stage 3 (major complication and progressive course or the 3 predictors).

  • †(I) with or without involvement of the pulmonary artery, but all patients had narrowing or occlusion in some region of the aorta or its main branches, or both; (II) one of the following: Takayasu’s retinopathy, secondary hypertension, aortic regurgitation, or aortic or arterial aneurysm; if mild or moderate complications (IIa), if severe complications (IIb); (III) two or more of the four complications mentioned above.

  • ESR, erythrocyte sedimentation rate; QUIPS, Quality in Prognosis Studies tool; RoB, risk of bias; TAK, Takayasu arteritis.